Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy
Jazyk angličtina Země Česko Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
28399389
DOI
10.14712/18059694.2017.44
PII: 18059694.2017.44
Knihovny.cz E-zdroje
- Klíčová slova
- anti-cancer treatment, benzimidazole carbamate, flubendazole, melanoma, microtubules, mitotic catastrophe,
- MeSH
- leukemie farmakoterapie MeSH
- lidé MeSH
- mebendazol analogy a deriváty terapeutické užití MeSH
- mikrotubuly metabolismus MeSH
- mnohočetný myelom farmakoterapie MeSH
- stárnutí buněk účinky léků MeSH
- tubulin metabolismus MeSH
- viabilita buněk MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- flubendazole MeSH Prohlížeč
- mebendazol MeSH
- tubulin MeSH
Flubendazole is a widely used anthelmintic drug belonging to benzimidazole group. The molecular mechanism of action of flubendazole is based on its specific binding to tubulin, which results in disruption of microtubule structure and function, and in the interference with the microtubule-mediated transport of secretory vesicles in absorptive tissues of helminths. The microtubule-disrupting properties of benzimidazole derivatives raised recently interest in these compounds as possible anti-cancer agents. In this minireview flubendazole effects towards selected human malignant cells including myeloma, leukemia, neuroblastoma, breast cancer, colorectal cancer and melanoma are discussed along with basic data on its pharmacokinetics, metabolism and toxicity.
Citace poskytuje Crossref.org
